
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva Inc has demonstrated strong financial performance with significant year-over-year sales growth, notably achieving a 33% increase in Giapreza sales from 2023 to 2024 and maintaining over 20% annual sales growth for Xerava since its acquisition. The company's strategic acquisitions have outperformed previous ownership, with annualized run rates for both Giapreza and Xerava nearly doubling since their acquisition in August 2022. Additionally, Giapreza's net sales have risen from $33.4 million in 2021 to $41.3 million in 2023, with projections suggesting further growth to $55 million in 2024, underscoring Innoviva’s effective management and growth potential in its healthcare portfolio.
Bears say
Innoviva Inc is projected to experience a decline in royalty revenues, with sales from GSK forecasted to decrease by an average of 8% year-over-year for Relvar/Breo and 4% for Anoro over the next eight years. Furthermore, the anticipated loss of exclusivity for Giapreza by 2034, combined with concerns about the diminishing efficacy of colistin against multi-drug-resistant strains, presents additional challenges for the company's future revenue streams. Despite potential barriers to generic competition, the company's overall financial outlook remains concerning due to these declining sales expectations and impending patent expirations.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares